Cargando…

SHP-1 is a target of regorafenib in colorectal cancer

Regorafenib is an inhibitor of multiple protein kinases which exerts antitumor and antimetastatic activities in metastatic colorectal cancer (CRC). SH2 domain-containing phosphatase 1 (SHP-1) is reported to have tumor suppressive potential because it acts as a negative regulator of p-STAT3(Tyr705) s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Li-Ching, Teng, Hao-Wei, Shiau, Chung-Wai, Lin, Hang, Hung, Man-Hsin, Chen, Yen-Lin, Huang, Jui-Wen, Tai, Wei-Tien, Yu, Hui-Chuan, Chen, Kuen-Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171626/ https://www.ncbi.nlm.nih.gov/pubmed/25071018

Ejemplares similares

Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2016)

Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer()()
por: Fan, Li-Ching, et al.
Publicado: (2015)

Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells
por: Chung, Shin-Yi, et al.
Publicado: (2018)

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells
por: Su, Jung-Chen, et al.
Publicado: (2014)

Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2013)

Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma
por: Hu, Ming-Hung, et al.
Publicado: (2017)

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
por: Su, Jung-Chen, et al.
Publicado: (2014)

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy
por: Huang, Tzu-Ting, et al.
Publicado: (2017)

SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
por: Hung, Man-Hsin, et al.
Publicado: (2015)

Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1
por: Su, Jung-Chen, et al.
Publicado: (2018)

Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis
por: Su, Jung-Chen, et al.
Publicado: (2016)

Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread
por: Hsu, Hung-Chih, et al.
Publicado: (2021)

Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma
por: Teng, Hao-Wei, et al.
Publicado: (2016)

Corrigendum: Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma
por: Teng, Hao-Wei, et al.
Publicado: (2017)

SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma
por: Tai, Wei-Tien, et al.
Publicado: (2016)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

Development and Validation of a Novel Serum Prognostic Marker for Patients with Metastatic Colorectal Cancer on Regorafenib Treatment
por: Su, Yu-Li, et al.
Publicado: (2021)

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study
por: Lin, Chun-Yu, et al.
Publicado: (2018)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Sorafenib analogue SC‐60 induces apoptosis through the SHP‐1/STAT3 pathway and enhances docetaxel cytotoxicity in triple‐negative breast cancer cells
por: Liu, Chun‐Yu, et al.
Publicado: (2017)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)

Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration
por: Yang, Cheng-Yi, et al.
Publicado: (2019)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

SHP2 inhibition improves celastrol-induced growth suppression of colorectal cancer
por: Zhang, Linxi, et al.
Publicado: (2022)

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma
por: Chen, Ji-Lin, et al.
Publicado: (2022)

Correction: Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration
por: Yang, Cheng-Yi, et al.
Publicado: (2019)

Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer
por: Song, Xiangping, et al.
Publicado: (2020)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Regorafenib: Adding to the Armamentarium for Refractory Colorectal Cancer and GIST
por: Roman, Danielle, et al.
Publicado: (2013)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
por: Yan, Yiyi, et al.
Publicado: (2015)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
por: Melosky, Barbara
Publicado: (2016)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Calpain/SHP-1 Interaction by Honokiol Dampening Peritoneal Dissemination of Gastric Cancer in nu/nu Mice
por: Liu, Shing Hwa, et al.
Publicado: (2012)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_166j3c4be7k2h198todvkvhau2